• 1
    Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005; 97: 966-975.
  • 2
    Haagensen CD, Stout AP. Carcinoma of the breast: II. Criteria of operability. Ann Surg. 1943; 118: 859-870.
  • 3
    Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the Breast Clinic of Memorial Hospital. Surg Gynecol Obstet. 1924; 39: 580.
  • 4
    Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995; 62: 382-385.
  • 5
    Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000; 2: 423-429.
  • 6
    Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 2005; 22: 67-73.
  • 7
    NCCN guidelines. Available at: Accessed on June 4, 2009.
  • 8
    Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994; 74: 466-476.
  • 9
    Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40: 321-329.
  • 10
    Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 1200-1208.
  • 11
    Bauer RL, Busch E, Levine E, Edge SB. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol. 1995; 2: 288-294.
  • 12
    Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004; 22: 4067-4074.
  • 13
    Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 14
    Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach—M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol. 1990; 27: 94-100.
  • 15
    Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg. 1994; 18: 87-92.
  • 16
    Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Oncol Clin N Am. 1995; 4: 715-734.
  • 17
    Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004; 4: 415-419.
  • 18
    Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005; 23: 1941-1950.
  • 19
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17: 460-469.
  • 20
    Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006; 106: 1000-1006.
  • 21
    Ellis GK. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer [abstract]. J Clin Oncol. 2006; 24(18 suppl):LBA 537.
  • 22
    Somlo G, Frankel P, Chow W, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004; 22: 1839-1848.
  • 23
    Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999; 81: 449-456.
  • 24
    Cheng YC, Rondon G, Yang Y, et al. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant. 2004; 10: 794-804.
  • 25
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
  • 26
    Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE. High incidence of HER-2 positivity in inflammatory breast cancer. Breast. 2004; 13: 97-103.
  • 27
    Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER-2 positive locally advanced breast cancer: primary efficiency analysis of the NDAH trial. Cancer Research. 2009; 69(2 suppl). Abstract 31.
  • 28
    Cristofanilli M. A phase II combination study of lapatanib and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer [abstract]. Breast Cancer Res Treat. 2006; 100: a1.
  • 29
    McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res. 2002; 8: 3857-3862.
  • 30
    Visscher DW, Smilanetz S, Drozdowicz S, Wykes SM. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol. 1993; 15: 88-92.
  • 31
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27-31.
  • 32
    Goon PK, Boos CJ, Lip GY. Circulating endothelial cells: markers of vascular dysfunction. Clin Lab. 2005; 51: 531-538.
  • 33
    Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438: 820-827.
  • 34
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
  • 35
    Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006; 24: 769-777.
  • 36
    Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res. 2008; 14: 5893-5899.
  • 37
    Overmoyer B, Fu P, Hoppel C, et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res. 2007; 13: 5862-5868.
  • 38
    Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007; 9: 115-119.
  • 39
    Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of 2 dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003; 21: 2492-2499.
  • 40
    National Institutes of Health. Available at: Accessed June 1, 2009.
  • 41
    National Institutes of Health. Available at: Accessed May 26, 2009.
  • 42
    Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer. 2006; 107: 2535-2544.
  • 43
    Vandebroek J. Efficacy and tolerance of epirubicin-docetaxel (E-T) in patients with inflammatory breast cancer (IBC) [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 210.
  • 44
    Ditsch N, Bauerfeind I, Kahlert S, et al. Subgroup Analysis of 101 inflammatory breast cancer patients treated within a prospective randomized trial of dose dense sequential versus standard anthracycline and taxane based primary chemotherapy (multicentre study of the AGO). 2006. Presented at the 27th German Cancer Congress Berlin 2006. German Cancer Society.
  • 45
    Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 2004; 10: 6215-6221.
  • 46
    Baldini E, Gardin G, Evagelista G, Prochilo T, Collecchi P, Lionetto R. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer. 2004; 5: 358-363.